default author photo

Eric Pujade-Lauraine

ARCAGY-GINECO

8 Rue Lamennais

Paris

France

SCHOLARLY PAPERS

3

DOWNLOADS

174

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study

Number of pages: 52 Posted: 28 Oct 2020
ARCAGY-GINECO, Saitama Medical University International Medical Center (SIMC), University College London - UCL Cancer Institute, University of Toronto - Princess Margaret Cancer Centre, University College London - UCL Cancer Institute, University of Claude Bernard Lyon 1 - Medical Oncology Department, Cabrini Hospital - Department of Medical Oncology, Ospedale San Giovanni - Oncology Institute of Southern Switzerland (IOSI), National Cancer Center Hospital - Department of Breast and Medical Oncology, Government of the United Kingdom - Royal Marsden NHS Foundation Trust, Université Paris XI Sud - Gustave Roussy Cancer Campus, BC Cancer, University of Ulsan - Department of Oncology, Poznan University of Medical Sciences - Department of Oncology, National Cancer Center - Center for Uterine CancerNational Cancer Center, Korea - Center for Gynecologic Cancer, Willamette Valley Cancer Institute and Research Center, Pfizer Oncology, Pfizer Oncology, Pfizer, Inc. - Pfizer Global Biometrics and Data Management, Pfizer Oncology and University of Arizona - College of Medicine, Arizona Oncology (US Oncology Network)
Downloads 101 (684,672)

Abstract:

Loading...

ovarian cancer, Avelumab, PD-L1, Phase 3, immune checkpoint inhibitor

2.

Early Clinical and Molecular Biomarkers in Advanced Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy: Chiva Phase Ii Gineco Trial

Number of pages: 22 Posted: 07 Oct 2024
University of Paris-Saclay - Institut Gustave Roussy, University of Paris-Saclay - Institut Gustave Roussy, Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, University of Claude Bernard Lyon 1 - Medical Oncology Department, affiliation not provided to SSRN, University of Lille II - Centre Oscar Lambret, Université de Caen, Institut Claudius Regaud, affiliation not provided to SSRN, Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Bordeaux - Institut Bergonié, University of Limoges - CHU Limoges, affiliation not provided to SSRN, Institut Mutualiste Montsouris, Western Cancer Institute, ARCAGY-GINECO, Gustave Roussy, Gustave Roussy, affiliation not provided to SSRN, Gustave Roussy and Université Paris XI Sud - Gustave Roussy Cancer Campus
Downloads 46 (1,109,210)

Abstract:

Loading...

Ovarian cancer, neoadjuvant chemotherapy, biomarkers, homologous recombination deficiency, TILS

3.

Adverse Events in the Placebo Arm of Solo2/Engot-Ov21 Maintenance Trial of Olaparib in Recurrent Ovarian Cancer

Number of pages: 27 Posted: 24 Sep 2024 Last Revised: 01 May 2025
The University of Sydney, The University of Sydney, The University of Sydney - NHMRC Clinical Trials Centre, Université de Caen, University College London - UCL Cancer Institute, Harvard University - Harvard Medical School, University of Toronto - University Health Network, Tel Aviv University, affiliation not provided to SSRN, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Saitama Medical University International Medical Center (SIMC), affiliation not provided to SSRN, affiliation not provided to SSRN, ARCAGY-GINECO and The University of Sydney
Downloads 27 (1,359,097)

Abstract:

Loading...

Placebo, adverse events, trial design, ovarian cancer, maintenance therapy, PARPi